EUSA Pharma (EUSA), is a global biopharmaceutical company that focuses on the treatment of oncology and other rare infections. The company was launched in March 2015. With many years of prosperity in delivering world-class products, the company has developed extensive commercial networks in the United States and around Europe, as well as the establishment of direct presence in other selected markets in the world.
EUSA Pharma is managed by a team of focused leaders who have many years of experience as well as recommendable records in developing successful pharmaceutical companies. The company also receives significant financial support from one of the leading life science investor, EW Healthcare Partners.
With the aims of improving the efficiency of service delivery, the company created new positions. It was on 15th May, when the company made the official announcement that it had appointed Dr. Carsten Thiel to fill the position of President in charge of the company’s affair in Europe and Dr. Darrel p. Cohen to take over the new post as the Head of Clinical Development.
Carsten Thiel is a well-known figure in the pharmaceutical and biopharmaceutical professions. Dr. Carsten Thiel, a Ph.D. holder, brings extensive experience of over 27 years gained serving in a variety of international roles in the pharmaceutical industry. Prior to this post, he was serving as the CEO of a US-based company, Abeona Therapeutics, as a gene therapy specialist. He also worked for several years at Alexion Pharmaceutical as the CEO where he led the company’s EMEA, Asia, Pacific, and Australasia organizations.
Carsten Thiel is an authority in biotechnology having spent a good number of years in the industry. He believes that the field has entered its golden age and the future holds a lot of promise. Answers to pertinent human concerns like living disease-free lives are sure to be addressed during this period. See This Page for additional information.
On the other hand, Dr. Darrel P. Cohen is a qualified oncologist specialist with two decades of clinical development experience in the pharmaceutical industry. Before joining EUSA, Dr. Cohen was a Vice President of Pfizer’s International Oncology firm where he led the company with remarkable achievements. He also worked at Duke University in the department of medicine where he served as an Associate Tutor and Oncology Fellow.